Jean Nichols
No más puestos en curso
Perfil
Jean Nichols was the President of Seragen, Inc. and Gloucester Pharmaceuticals, Inc. before becoming the Chief Operating Officer of Stonegate Partners LLC.
Prior to her business career, she was a Faculty Member at Harvard University.
Nichols holds an undergraduate and doctorate degree from The University of North Carolina at Charlotte.
Antiguos cargos conocidos de Jean Nichols.
Empresas | Cargo | Fin |
---|---|---|
Gloucester Pharmaceuticals, Inc.
Gloucester Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Gloucester Pharmaceuticals, Inc. develops products for the treatment of cancer patients. Its programs include cutaneous T-cell lymphoma (CTCL), peripheral T-cell lymphoma (PTCL), and multiple myeloma. The company was founded in May 2003 and is headquartered in Cambridge, MA | Presidente | 26/04/2011 |
Harvard University
Harvard University Other Consumer ServicesConsumer Services Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - |
Stonegate Partners LLC
Stonegate Partners LLC Financial ConglomeratesFinance Stonegate Partners LLC is a private equity firm. | Director de Operaciones | - |
Seragen, Inc.
Seragen, Inc. Pharmaceuticals: MajorHealth Technology Part of Ligand Pharmaceuticals, Inc., Seragen, Inc. develops drugs. The company is based in Westerly, RI. Seragen was acquired by Ligand Pharmaceuticals, Inc. on August 12, 1998 for $57.96 million. | Presidente | - |
Formación de Jean Nichols.
The University of North Carolina at Charlotte | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas privadas | 3 |
---|---|
Gloucester Pharmaceuticals, Inc.
Gloucester Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Gloucester Pharmaceuticals, Inc. develops products for the treatment of cancer patients. Its programs include cutaneous T-cell lymphoma (CTCL), peripheral T-cell lymphoma (PTCL), and multiple myeloma. The company was founded in May 2003 and is headquartered in Cambridge, MA | Health Technology |
Seragen, Inc.
Seragen, Inc. Pharmaceuticals: MajorHealth Technology Part of Ligand Pharmaceuticals, Inc., Seragen, Inc. develops drugs. The company is based in Westerly, RI. Seragen was acquired by Ligand Pharmaceuticals, Inc. on August 12, 1998 for $57.96 million. | Health Technology |
Stonegate Partners LLC
Stonegate Partners LLC Financial ConglomeratesFinance Stonegate Partners LLC is a private equity firm. | Finance |
- Bolsa de valores
- Insiders
- Jean Nichols